Protalix BioTherapeutics, Inc. (NYSEMKT:PLX)

CAPS Rating: 3 out of 5

A clinical stage biopharmaceutical company that is focused on developing and manufacturing recombinant therapeutic proteins that are produced through its proprietary plant cell system.

Results 1 - 20 of 33 : 1 2 Next »

Recs

0
Member Avatar SqwiiTrader (< 20) Submitted: 11/5/2013 2:56:24 PM : Outperform Start Price: $4.40 PLX Score: -52.32

IHS pattern

Recs

2
Member Avatar TMFBlacknGold (98.84) Submitted: 10/22/2013 12:56:17 AM : Outperform Start Price: $4.38 PLX Score: -53.63

It's stupid how easy this is. Protalix may have a long way to go in terms of developing its pipeline, but I imagine quite a few pharma companies are eyeing its biomanufacturing capabilities. The ability to greatly reduce the cost of manufacturing biologic drugs, which traditionally cost more than synthetically-produced small molecules, will be too good to ignore in due time. The market for enzyme replacement therapies alone will be worth well over several billion dollars per year. If oral drugs such as PRX-112 prove successful, then consider Protalix a slam dunk.

Who would be interested? Amgen invests billions in flexible biomanufacturing each year, and Pfizer is already a partner on Elelyso. Additionally, you can't rule out other big pharma companies that are even more desperate for a boost. Perhaps the company's plant cell-based TNF-alpha inhibitor is too late to the party considering the arrival of next generation drugs such as Jonhson & Johnson's Stelara. Then again, perhaps it can stick around just as long as Enbrel, which has the longest lasting patents of the original Big Three. I consider that program funny money for valuing Protalix.

At the end of the day, Protalix is an incredible long term buy at these prices. It really doesn't get much easier for biotech investors.

Previous articles:
Can Protalix Revolutionize This Orphan Disease? (PRX-112):
http://www.fool.com/investing/general/2013/10/15/can-protalix-revolutionize-this-orphan-disease.aspx

Should You Buy Protalix for Its Platform Alone?:
http://www.fool.com/investing/general/2013/09/22/should-you-buy-protalix-for-its-platform-alone.aspx

How Far Can $69 Million Take Protalix?:
http://www.fool.com/investing/general/2013/09/18/how-far-can-69-million-take-protalix.aspx

Enjoy!

--Maxxwell

Recs

1
Member Avatar zzlangerhans (99.82) Submitted: 8/19/2012 2:05:17 AM : Outperform Start Price: $5.50 PLX Score: -89.67

I always get an uneasy feeling when I green thumb a stock like Protalix because I don't trust the company and I especially don't trust former chairman Philip Frost. Does he still have his fingers in this pie? Your guess is as good as mine. As far as I'm concerned, nothing he is involved with is investment grade. That being said, the company has managed to get a potentially lucrative drug approved and they have the ability to compete with the established therapies due to lower manufacturing costs. This could certainly blow up disastrously but I'm willing to kick in an outperform pending initial sales data.

Recs

1
Member Avatar TMFBiologyFool (96.90) Submitted: 5/2/2012 12:24:24 PM : Underperform Start Price: $7.02 PLX Score: +100.94

Low patient numbers + 2 competitors = tough launch.

I actually like the manufacturing technology, but next drug is still years away.

Recs

0
Member Avatar sunvestor7 (< 20) Submitted: 3/10/2012 5:47:39 PM : Outperform Start Price: $5.55 PLX Score: -94.39

the disruptive technology that will change the biologics. They have had setbacks ---but their time now has come. With approval for gaucher and validation of technology platform sky is the limit

Recs

0
Member Avatar YORGILL (< 20) Submitted: 3/11/2011 2:05:26 PM : Outperform Start Price: $6.25 PLX Score: -106.75

Great innovative platform with big potential for biosimilars

Recs

0
Member Avatar reachmygoals1 (< 20) Submitted: 1/29/2011 4:23:49 PM : Outperform Start Price: $9.28 PLX Score: -122.30

$20 after fda approval...over $30 if they get a buyout after fda approval

Recs

0
Member Avatar eitanbilu (< 20) Submitted: 12/8/2010 11:22:53 AM : Outperform Start Price: $8.68 PLX Score: -126.82

no doubts !

Recs

0
Member Avatar Biotech2010 (53.99) Submitted: 1/26/2010 8:50:26 PM : Outperform Start Price: $7.25 PLX Score: -140.66

@7.02

Recs

0
Member Avatar luebypopoff (27.95) Submitted: 12/30/2009 7:37:33 PM : Outperform Start Price: $6.70 PLX Score: -132.33

Shorts are driving stock down, but has deal with Pfizer, a new drug about to be released, and others in the pipeline.

Recs

0
Member Avatar movadoman51 (< 20) Submitted: 11/4/2009 12:37:36 AM : Outperform Start Price: $10.93 PLX Score: -158.04

New technology!!! will bit all pharma co.

Recs

0
Member Avatar Displacement (< 20) Submitted: 9/28/2009 4:24:48 PM : Outperform Start Price: $8.27 PLX Score: -149.16

Surprising performance for my contrarians' box

Recs

0
Member Avatar Thelmal (57.93) Submitted: 9/25/2009 8:07:36 AM : Outperform Start Price: $7.60 PLX Score: -149.51

Forward thinking Biotech Company

Recs

0
Member Avatar hrefael77 (< 20) Submitted: 9/2/2009 1:19:08 PM : Outperform Start Price: $7.10 PLX Score: -156.36

SUCCESEE IN THE iii PHASE

Recs

0
Member Avatar yshoshany (< 20) Submitted: 7/24/2009 9:25:07 AM : Outperform Start Price: $6.20 PLX Score: -157.32

great technology

Recs

0
Member Avatar LandWayland (< 20) Submitted: 7/17/2009 8:15:38 PM : Outperform Start Price: $5.48 PLX Score: -157.49

This company has developed a radical new technology for cheaply generating biological components for making complex drugs. Their first drug has successfully completed FDA Phase III trials and will soon be on the market with a potential annual sales in excess of $1 billion.

Recs

0
Member Avatar floyd28 (< 20) Submitted: 7/16/2009 11:11:08 PM : Outperform Start Price: $5.56 PLX Score: -159.40

Protalix is re inventing the wheel and that means it will be probably bought by a bigger company in a high price which will make the holders happy.
If it wont be bought (or wont be sold) then I personally believe it will be a major player and the stock's price right now will sound like a joke in a few years from now.

A risk, yes! but today most investments have risks within them at least here we know that the reward can be worthwhile.

That is my personal opinion only - not a recommendation!

Recs

0
Member Avatar esqdrew (< 20) Submitted: 6/27/2009 8:20:16 PM : Outperform Start Price: $4.90 PLX Score: -157.79

Because Philip Frost is involved and because PLX is in Phase III of its testing of prGCD and if the results turn out well this stock will explode.

Recs

0
Member Avatar crapsshooter (75.91) Submitted: 2/13/2009 12:21:14 PM : Outperform Start Price: $2.64 PLX Score: -139.99

There have been no Serious Adverse Events reported in connection with the phase III clinical trial. I bought in at 1.38 and this has been going up so therefore i am going very long

Recs

3
Member Avatar yellowear (34.26) Submitted: 12/20/2008 12:32:36 PM : Outperform Start Price: $1.62 PLX Score: -65.49

Based on the news on the street and the performance of the stock at these levels, this company has the potential of reaching 2000% in the next 4 years. This stock has found a bottom like AKS did several years ago which reached a high of 70+ before it cratered. This is a 'Just about Perfect' time to start to buy this stock!

Results 1 - 20 of 33 : 1 2 Next »

Featured Broker Partners


Advertisement